Molecular Tumor Profiling

The development of targeted cancer therapies has led to improved clinical outcomes for many patients. However, monotherapies against a single target can result in treatment resistance.

A first-ever pediatric blue book has been developed as part of the fifth edition of the WHO Classification of Tumors series.

In this vide, David R. Gandara, MD, spoke with Healio about the molecular tumor board discussion at the International Lung Cancer Congress.

Molecular profiling of solid tumors in children and young adults has a significant impact on diagnosis and treatment recommendations, according to results of an interim analysis presented during the virtual ASCO Annual Meeting.